Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin的应助被张钧凯采纳,获得10
刚刚
1秒前
dabin完成签到,获得积分20
1秒前
2秒前
2秒前
哈哈哈完成签到 ,获得积分10
3秒前
自觉芒果完成签到 ,获得积分10
4秒前
4秒前
4秒前
eee完成签到 ,获得积分10
4秒前
科研通AI6.4的应助被sunshine采纳,获得10
4秒前
6秒前
充电宝的应助被kenan采纳,获得10
7秒前
ZzzZzH发布了新的文献求助10
7秒前
dabin发布了新的文献求助20
7秒前
mmm发布了新的文献求助10
8秒前
CC关闭了CC的文献求助
8秒前
zaian完成签到,获得积分10
8秒前
9秒前
9秒前
木耳2号完成签到,获得积分10
10秒前
rui2820完成签到,获得积分10
11秒前
孙小子完成签到,获得积分10
11秒前
Tigher完成签到,获得积分10
11秒前
11秒前
羽毛笔完成签到,获得积分10
11秒前
科研通AI6.4的应助被eee采纳,获得10
11秒前
月子完成签到 ,获得积分10
12秒前
小马甲的应助被研友_EZ1oWL采纳,获得10
13秒前
13秒前
ZXW完成签到,获得积分10
13秒前
14秒前
222666完成签到,获得积分10
14秒前
FashionBoy的应助被nanting采纳,获得10
14秒前
Lucas的应助被ZzzZzH采纳,获得10
15秒前
搜集达人的应助被风韵犹存采纳,获得10
16秒前
16秒前
哈哈哈77发布了新的文献求助10
16秒前
kevin发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Les Mantodea De Guyane 2000
Guidelines for fracture-safe and fatigue-reliable design of steel structures 600
The Basics of Practical Optimization, Second Edition 600
Problems and Solutions for Integer and Combinatorial Optimization: Building Skills in Discrete Optimization 600
Organizational Behavior 510
Atelier, 2nd edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 7991643
求助须知:如何正确求助?哪些是违规求助? 9447444
关于积分的说明 21111908
捐赠科研通 7564807
什么是DOI,文献DOI怎么找? 3378572
关于科研通互助平台的介绍 2512466
邀请新用户注册赠送积分活动 2412112